"There should be no shortage of biotech companies
Post# of 72440
Michael Yee’s team at Jefferies gathered the numbers for the last few years and tracked the tens of billions in cash that is being pumped into biotech startups. A few salient points emerge:
Annual venture funding in life sciences has grown from the $8-to-$10 billion range 5 years ago to the $20-to-$30 billion range today.
In just two years, the average number of venture rounds per quarter has doubled — growing from 20-30 every 3 months in 2017 to 40 to 60. And there have been 18 rounds of more than $100 million so far this year.
That all sets up an even more heated comparison of the newly effervescent M&A market for startups compared to the search for public investors — a trend that has fueled a much larger migration to commercialization work among small and mid-cap biotechs. And it’s all playing out in the short term during an unprecedented bull market for biotech."